Profile state: payments and partdOpen Payments: 2025Medicare Part D: 2024Last identity check: 2026-08-10Page data build: 2026-08-12
Verified facts
What the public records show
CMS Open Payments records show George C Parides, DO received $132,101.37 in general payments during 2025 across 144 reported records.
AstraZeneca Pharmaceuticals LP accounted for 98.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
General Payments
$132,101.37
144 reported records · 2 companies
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
Reported company
Canonical company
Amount
Share
Records
Year
AstraZeneca Pharmaceuticals LP
Unresolved — no canonical attribution shown
$130,101.37
98.5%
143
2025
Verona Pharma, Inc.
Unresolved — no canonical attribution shown
$2,000.00
1.5%
1
2025
What were the payments for?
Payment categories
Category
Amount
Records
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
$115,175.00
48
Travel and Lodging
$13,366.06
48
Food and Beverage
$3,560.31
48
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
Paying company
Payment year
Drug reported by same entity
Open Payments evidence
Part D
Claims
Beneficiaries
AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference
2025
BEVESPI AEROSPHERE open payments reported associated product
Symbicort · 2024 Exact normalized brand match · 1 Part D row
135
34
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
Brand
Generic
Claims
Beneficiaries
Albuterol Sulfate Hfa
Albuterol Sulfate
405
151
Breztri Aerosphere
Budesonide/Glycopyr/Formoterol
333
77
Montelukast Sodium
Montelukast Sodium
232
66
Trelegy Ellipta
Fluticasone/Umeclidin/Vilanter
192
39
Prednisone
Prednisone
167
77
Azithromycin
Azithromycin
149
78
Symbicort
Budesonide/Formoterol Fumarate
135
34
Breo Ellipta
Fluticasone/Vilanterol
93
23
Doxycycline Hyclate
Doxycycline Hyclate
68
38
Omeprazole
Omeprazole
67
15
Advair Hfa
Fluticasone Propion/Salmeterol
59
12
Fluticasone-Salmeterol
Fluticasone Propion/Salmeterol
53
15
Amoxicillin-Clavulanate Potass
Amoxicillin/Potassium Clav
51
25
Breyna
Budesonide/Formoterol Fumarate
50
20
Bevespi Aerosphere
Glycopyrrolate/Formoterol Fum
36
suppressed
Spiriva Respimat
Tiotropium Bromide
33
suppressed
Wixela Inhub
Fluticasone Propion/Salmeterol
32
15
Stiolto Respimat
Tiotropium Br/Olodaterol Hcl
30
suppressed
Dulera
Mometasone/Formoterol
29
suppressed
Fluticasone Propionate
Fluticasone Propionate
29
11
Anoro Ellipta
Umeclidinium Brm/Vilanterol Tr
27
suppressed
Fluconazole
Fluconazole
27
suppressed
Combivent Respimat
Ipratropium/Albuterol Sulfate
26
suppressed
Atrovent Hfa
Ipratropium Bromide
23
suppressed
Famotidine
Famotidine
23
suppressed
Roflumilast
Roflumilast
17
suppressed
Incruse Ellipta
Umeclidinium Bromide
16
suppressed
Advair Diskus
Fluticasone Propion/Salmeterol
14
suppressed
Levalbuterol Tartrate Hfa
Levalbuterol Tartrate
13
suppressed
Ventolin Hfa
Albuterol Sulfate
13
suppressed
Budesonide-Formoterol Fumarate
Budesonide/Formoterol Fumarate
12
suppressed
Ipratropium Bromide
Ipratropium Bromide
12
suppressed
Azelastine Hcl
Azelastine Hcl
11
suppressed
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
Year
General Payments
Main payer
Explicit products
Company overlaps
Part D coverage
2025
$132,101.37 · 144 records
AstraZeneca Pharmaceuticals LP
AIRSUPRA, BREZTRI, FASENRA, Ohtuvayre
2
—
2024
—
—
—
—
Complete
Questions to ask
Questions you could discuss with your doctor
How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.